patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1 value | histology stringclasses 3 values | stage_at_diagnosis stringclasses 3 values | driver_mutation stringclasses 7 values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2 values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6 values | overall_survival_months float64 4 83 | censored bool 2 classes | msi_status stringclasses 2 values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1 value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_908235 | REC_0000601 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 13.4 | 70 | female | 1 | 14 | 5.4 | 5 | alectinib 600 mg BID | 9.9 | false | MSI-H | 2026-03-15T05:35:56.983892+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_353828 | REC_0000602 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 4.5 | 73 | female | 2 | 14 | 3.5 | 5 | osimertinib 80 mg daily | 4.7 | true | MSS | 2026-03-15T05:35:56.984257+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_976641 | REC_0000603 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 27 | 6.3 | 62 | male | 1 | 24 | 7.4 | 0 | osimertinib 80 mg daily | 43.5 | false | MSS | 2026-03-15T05:35:56.984511+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_480445 | REC_0000604 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 15.1 | 57 | female | 1 | 16 | 5.4 | 7 | osimertinib 80 mg daily | 7.2 | false | MSI-H | 2026-03-15T05:35:56.984754+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_438995 | REC_0000605 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 7.6 | 65 | male | 1 | 16 | 5.3 | 5 | entrectinib 600 mg daily | 6.9 | true | MSS | 2026-03-15T05:35:56.984988+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_954552 | REC_0000606 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 14.5 | 69 | female | 0 | 25 | 4.8 | 4 | osimertinib 80 mg daily | 16 | true | MSS | 2026-03-15T05:35:56.985221+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_730343 | REC_0000607 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 15 | 83 | female | 1 | 13 | 8.5 | 6 | alectinib 600 mg BID | 9.5 | false | MSS | 2026-03-15T05:35:56.985455+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_975887 | REC_0000608 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 7.1 | 70 | male | 1 | 10 | 5.8 | 2 | osimertinib 80 mg daily | 6.6 | false | MSS | 2026-03-15T05:35:56.985685+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_784478 | REC_0000609 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 25 | 5.7 | 67 | female | 1 | 79 | 5.7 | 1 | pembrolizumab 200 mg q3w | 19.2 | true | MSS | 2026-03-15T05:35:56.985913+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_693645 | REC_0000610 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 20 | 9.7 | 50 | male | 0 | 22 | 6.1 | 0 | alectinib 600 mg BID | 38.1 | true | MSS | 2026-03-15T05:35:56.986148+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_244233 | REC_0000611 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 13.9 | 60 | female | 1 | 14 | 6.6 | 2 | alectinib 600 mg BID | 9.2 | false | MSS | 2026-03-15T05:35:56.986383+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_918738 | REC_0000612 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 13.6 | 67 | female | 0 | 10 | 7 | 6 | entrectinib 600 mg daily | 10.5 | true | MSI-H | 2026-03-15T05:35:56.986743+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_711509 | REC_0000613 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 15.9 | 66 | female | 1 | 11 | 4.5 | 1 | alectinib 600 mg BID | 20.9 | false | MSI-H | 2026-03-15T05:35:56.987034+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_668015 | REC_0000614 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 12.5 | 58 | female | 0 | 20 | 6.2 | 6 | osimertinib 80 mg daily | 9.1 | true | MSI-H | 2026-03-15T05:35:56.987273+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_159809 | REC_0000615 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 22 | 11.5 | 65 | female | 0 | 26 | 5.9 | 0 | osimertinib 80 mg daily | 22.7 | false | MSS | 2026-03-15T05:35:56.987542+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_561297 | REC_0000616 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 13.4 | 79 | female | 2 | 15 | 4.2 | 7 | alectinib 600 mg BID | 13.8 | true | MSI-H | 2026-03-15T05:35:56.987806+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_611942 | REC_0000617 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 8.5 | 61 | female | 1 | 9 | 5.1 | 6 | alectinib 600 mg BID | 11.1 | false | MSS | 2026-03-15T05:35:56.988042+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_748722 | REC_0000618 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 12.3 | 75 | female | 0 | 18 | 6.2 | 4 | entrectinib 600 mg daily | 16.6 | true | MSS | 2026-03-15T05:35:56.988330+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_441663 | REC_0000619 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 21 | 7.4 | 76 | female | 1 | 21 | 6.8 | 4 | pembrolizumab 200 mg q3w | 10.7 | false | MSS | 2026-03-15T05:35:56.988566+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_576806 | REC_0000620 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 6.7 | 69 | female | 1 | 66 | 5.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 24.6 | true | MSS | 2026-03-15T05:35:56.988797+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_920759 | REC_0000621 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 9 | 80 | male | 0 | 22 | 6.1 | 7 | alectinib 600 mg BID | 10.7 | true | MSS | 2026-03-15T05:35:56.989032+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_504653 | REC_0000622 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 17.1 | 77 | female | 1 | 21 | 6.1 | 7 | osimertinib 80 mg daily | 7.8 | true | MSI-H | 2026-03-15T05:35:56.989261+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_217215 | REC_0000623 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 13.8 | 62 | female | 1 | 33 | 5.6 | 1 | alectinib 600 mg BID | 15.8 | false | MSI-H | 2026-03-15T05:35:56.989501+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_234457 | REC_0000624 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 11.1 | 71 | female | 1 | 20 | 6 | 7 | entrectinib 600 mg daily | 15.4 | true | MSI-H | 2026-03-15T05:35:56.989731+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_293786 | REC_0000625 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 16 | 13.6 | 52 | female | 0 | 27 | 5.4 | 1 | alectinib 600 mg BID | 21.7 | false | MSI-H | 2026-03-15T05:35:56.990029+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_262645 | REC_0000626 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 6.9 | 73 | male | 0 | 22 | 6.5 | 8 | carboplatin + paclitaxel + pembrolizumab | 17.2 | false | MSS | 2026-03-15T05:35:56.990266+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_629374 | REC_0000627 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 30 | 6.1 | 71 | female | 1 | 22 | 4.4 | 5 | pembrolizumab 200 mg q3w | 5.6 | true | MSS | 2026-03-15T05:35:56.990499+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_780162 | REC_0000628 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 21.8 | 63 | female | 1 | 21 | 5.4 | 1 | entrectinib 600 mg daily | 20.7 | false | MSS | 2026-03-15T05:35:56.990737+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_362214 | REC_0000629 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 10.8 | 57 | female | 1 | 15 | 5.2 | 7 | pembrolizumab 200 mg q3w | 11.6 | false | MSI-H | 2026-03-15T05:35:56.991030+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_417914 | REC_0000630 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 7.5 | 67 | female | 1 | 71 | 6.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 15.9 | true | MSS | 2026-03-15T05:35:56.991263+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_346270 | REC_0000631 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 10.7 | 69 | female | 1 | 17 | 4 | 7 | sotorasib 960 mg daily | 8.4 | false | MSI-H | 2026-03-15T05:35:56.991531+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_284926 | REC_0000632 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 6.1 | 58 | female | 1 | 37 | 5.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.1 | false | MSS | 2026-03-15T05:35:56.991766+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_844004 | REC_0000633 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 34 | 10.7 | 72 | male | 2 | 40 | 6.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 15.2 | false | MSI-H | 2026-03-15T05:35:56.992037+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_580611 | REC_0000634 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 8 | 78 | female | 1 | 12 | 5.5 | 4 | entrectinib 600 mg daily | 14.7 | false | MSS | 2026-03-15T05:35:56.992322+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_153088 | REC_0000635 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 3.5 | 65 | male | 0 | 42 | 5.1 | 5 | pembrolizumab 200 mg q3w | 7.6 | false | MSS | 2026-03-15T05:35:56.992566+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_280810 | REC_0000636 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 4.7 | 67 | female | 0 | 0 | 6.1 | 2 | osimertinib 80 mg daily | 15.8 | true | MSS | 2026-03-15T05:35:56.992802+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_420120 | REC_0000637 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 6.7 | 64 | male | 0 | 35 | 6.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 9.6 | true | MSS | 2026-03-15T05:35:56.993038+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_472045 | REC_0000638 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 12.4 | 63 | female | 1 | 24 | 6.8 | 2 | osimertinib 80 mg daily | 20.9 | false | MSS | 2026-03-15T05:35:56.993380+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_373568 | REC_0000639 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 6 | 72 | female | 2 | 57 | 6.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.7 | true | MSS | 2026-03-15T05:35:56.993626+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_118118 | REC_0000640 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 13.3 | 72 | female | 1 | 18 | 7 | 1 | alectinib 600 mg BID | 12.4 | true | MSI-H | 2026-03-15T05:35:56.993862+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_201122 | REC_0000641 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 6.8 | 81 | female | 1 | 55 | 2.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 19.3 | false | MSS | 2026-03-15T05:35:56.994091+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_437521 | REC_0000642 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 8 | 53 | male | 0 | 20 | 4.5 | 2 | osimertinib 80 mg daily | 8.5 | false | MSS | 2026-03-15T05:35:56.994323+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_253609 | REC_0000643 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 5.6 | 68 | female | 1 | 21 | 4.8 | 2 | alectinib 600 mg BID | 15.9 | false | MSS | 2026-03-15T05:35:56.994551+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_123977 | REC_0000644 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 18.5 | 86 | female | 1 | 4 | 5.8 | 5 | osimertinib 80 mg daily | 13 | false | MSI-H | 2026-03-15T05:35:56.994782+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_353744 | REC_0000645 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 8.1 | 79 | female | 0 | 5 | 6.6 | 11 | alectinib 600 mg BID | 12.2 | false | MSS | 2026-03-15T05:35:56.995010+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_441052 | REC_0000646 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 5.8 | 78 | female | 1 | 54 | 3.4 | 4 | pembrolizumab 200 mg q3w | 9.4 | false | MSS | 2026-03-15T05:35:56.995241+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_910340 | REC_0000647 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 13 | 67 | female | 0 | 28 | 7.5 | 5 | entrectinib 600 mg daily | 12.7 | false | MSS | 2026-03-15T05:35:56.995484+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_194282 | REC_0000648 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 17.3 | 65 | female | 0 | 7 | 5.3 | 4 | alectinib 600 mg BID | 7.9 | false | MSS | 2026-03-15T05:35:56.995719+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_284384 | REC_0000649 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 12.5 | 62 | male | 1 | 12 | 6.2 | 5 | entrectinib 600 mg daily | 8.6 | false | MSS | 2026-03-15T05:35:56.995956+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_538750 | REC_0000650 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 10.7 | 72 | female | 0 | 21 | 5.9 | 4 | osimertinib 80 mg daily | 8.2 | true | MSI-H | 2026-03-15T05:35:56.996292+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_896012 | REC_0000651 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 13 | 79 | male | 2 | 11 | 4.1 | 2 | sotorasib 960 mg daily | 11.4 | true | MSS | 2026-03-15T05:35:56.996621+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_768181 | REC_0000652 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 15.7 | 70 | male | 2 | 6 | 5.1 | 4 | osimertinib 80 mg daily | 12.8 | true | MSS | 2026-03-15T05:35:56.996863+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_729416 | REC_0000653 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 9.6 | 80 | female | 2 | 17 | 5 | 2 | sotorasib 960 mg daily | 22.5 | true | MSS | 2026-03-15T05:35:56.997093+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_286167 | REC_0000654 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 31 | 7.7 | 55 | female | 0 | 13 | 6.8 | 2 | sotorasib 960 mg daily | 18 | true | MSS | 2026-03-15T05:35:56.997327+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_986963 | REC_0000655 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 11 | 12.7 | 69 | female | 1 | 14 | 5.8 | 1 | osimertinib 80 mg daily | 16.4 | true | MSS | 2026-03-15T05:35:56.997562+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_882963 | REC_0000656 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 9.4 | 66 | female | 0 | 24 | 4.4 | 2 | entrectinib 600 mg daily | 21.1 | false | MSS | 2026-03-15T05:35:56.997790+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_490896 | REC_0000657 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 22 | 11.1 | 80 | female | 2 | 16 | 5.6 | 0 | osimertinib 80 mg daily | 33 | false | MSS | 2026-03-15T05:35:56.998024+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_864066 | REC_0000658 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 20 | 7.8 | 70 | female | 1 | 0 | 5.6 | 0 | pembrolizumab 200 mg q3w | 26.6 | false | MSS | 2026-03-15T05:35:56.998253+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144396 | REC_0000659 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 32 | 6.6 | 68 | female | 0 | 17 | 3.9 | 0 | alectinib 600 mg BID | 26.6 | true | MSS | 2026-03-15T05:35:56.998484+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_484947 | REC_0000660 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 7.7 | 66 | female | 1 | 37 | 5.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.1 | false | MSS | 2026-03-15T05:35:56.998723+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_796892 | REC_0000661 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 6.3 | 78 | female | 2 | 34 | 5.3 | 7 | carboplatin + paclitaxel + pembrolizumab | 12.5 | true | MSS | 2026-03-15T05:35:56.998973+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_187013 | REC_0000662 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 13.5 | 72 | female | 0 | 8 | 9.6 | 7 | sotorasib 960 mg daily | 12.2 | false | MSI-H | 2026-03-15T05:35:56.999224+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_876415 | REC_0000663 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 17.6 | 79 | male | 1 | 7 | 5.8 | 6 | alectinib 600 mg BID | 14.1 | true | MSS | 2026-03-15T05:35:56.999482+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_751184 | REC_0000664 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 8.7 | 65 | male | 0 | 12 | 3.2 | 3 | sotorasib 960 mg daily | 21.7 | true | MSS | 2026-03-15T05:35:56.999853+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_469814 | REC_0000665 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 16.5 | 73 | female | 1 | 9 | 8.2 | 2 | osimertinib 80 mg daily | 24.4 | true | MSS | 2026-03-15T05:35:57.000180+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_930467 | REC_0000666 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 11.5 | 56 | male | 1 | 13 | 4.9 | 2 | entrectinib 600 mg daily | 8 | false | MSI-H | 2026-03-15T05:35:57.000436+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356945 | REC_0000667 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 11.9 | 60 | male | 1 | 16 | 3.9 | 3 | osimertinib 80 mg daily | 16.8 | false | MSS | 2026-03-15T05:35:57.000677+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_637858 | REC_0000668 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 10.6 | 71 | female | 1 | 0 | 2.5 | 2 | alectinib 600 mg BID | 10.3 | true | MSS | 2026-03-15T05:35:57.000915+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_810584 | REC_0000669 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 12.8 | 70 | female | 1 | 14 | 3.2 | 1 | osimertinib 80 mg daily | 11.5 | false | MSI-H | 2026-03-15T05:35:57.001148+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_253763 | REC_0000670 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 14.6 | 72 | female | 1 | 11 | 5.7 | 5 | osimertinib 80 mg daily | 9.9 | false | MSI-H | 2026-03-15T05:35:57.001380+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_125984 | REC_0000671 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 17 | 3.6 | 65 | male | 0 | 11 | 4.4 | 4 | pembrolizumab 200 mg q3w | 8 | false | MSS | 2026-03-15T05:35:57.001619+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_820966 | REC_0000672 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 27 | 6.6 | 64 | female | 0 | 15 | 6.2 | 1 | pembrolizumab 200 mg q3w | 6.8 | true | MSS | 2026-03-15T05:35:57.001906+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_580031 | REC_0000673 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 9.9 | 58 | female | 0 | 24 | 7.3 | 7 | osimertinib 80 mg daily | 8.8 | false | MSS | 2026-03-15T05:35:57.002146+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_867672 | REC_0000674 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 5.1 | 61 | female | 0 | 47 | 6.4 | 7 | carboplatin + paclitaxel + pembrolizumab | 8.9 | true | MSS | 2026-03-15T05:35:57.002379+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_671734 | REC_0000675 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 12.4 | 77 | female | 2 | 22 | 4.2 | 2 | alectinib 600 mg BID | 14.1 | false | MSI-H | 2026-03-15T05:35:57.002613+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_921449 | REC_0000676 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 24 | 4.8 | 68 | female | 1 | 54 | 7.2 | 0 | pembrolizumab 200 mg q3w | 41.9 | false | MSS | 2026-03-15T05:35:57.002845+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_101326 | REC_0000677 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 16 | 3.3 | 57 | female | 1 | 32 | 4.9 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.4 | true | MSS | 2026-03-15T05:35:57.003161+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_152383 | REC_0000678 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 9.8 | 82 | female | 2 | 9 | 6 | 7 | osimertinib 80 mg daily | 10.9 | false | MSS | 2026-03-15T05:35:57.003396+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_527355 | REC_0000679 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 14.5 | 64 | female | 1 | 19 | 6.2 | 7 | alectinib 600 mg BID | 9.5 | false | MSI-H | 2026-03-15T05:35:57.003636+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_829046 | REC_0000680 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 7.1 | 58 | male | 1 | 8 | 6.1 | 2 | entrectinib 600 mg daily | 14.3 | true | MSS | 2026-03-15T05:35:57.003868+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_507866 | REC_0000681 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 12.8 | 61 | male | 0 | 17 | 5.5 | 2 | sotorasib 960 mg daily | 15.3 | true | MSI-H | 2026-03-15T05:35:57.004186+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_590155 | REC_0000682 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 15.8 | 63 | male | 0 | 6 | 6.7 | 2 | sotorasib 960 mg daily | 14.5 | false | MSS | 2026-03-15T05:35:57.004435+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_890448 | REC_0000683 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 9.7 | 61 | male | 1 | 20 | 7.7 | 1 | alectinib 600 mg BID | 23.4 | false | MSS | 2026-03-15T05:35:57.004672+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_753878 | REC_0000684 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 33 | 10.5 | 64 | male | 0 | 26 | 4.8 | 5 | entrectinib 600 mg daily | 12.6 | false | MSS | 2026-03-15T05:35:57.004908+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_384845 | REC_0000685 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 4.6 | 63 | male | 1 | 59 | 4.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 14.4 | false | MSS | 2026-03-15T05:35:57.005143+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_462903 | REC_0000686 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 14.6 | 65 | female | 1 | 24 | 6.8 | 6 | osimertinib 80 mg daily | 13.8 | true | MSI-H | 2026-03-15T05:35:57.005377+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_846364 | REC_0000687 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 12.9 | 73 | female | 1 | 21 | 5.5 | 2 | pembrolizumab 200 mg q3w | 22.5 | true | MSS | 2026-03-15T05:35:57.005608+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_426166 | REC_0000688 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 14.9 | 43 | male | 0 | 14 | 5.1 | 1 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:57.005844+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_552099 | REC_0000689 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 4.7 | 72 | female | 1 | 11 | 5.8 | 4 | pembrolizumab 200 mg q3w | 5.4 | true | MSS | 2026-03-15T05:35:57.006072+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_533752 | REC_0000690 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 10.8 | 59 | male | 0 | 14 | 5.9 | 4 | alectinib 600 mg BID | 12.7 | true | MSI-H | 2026-03-15T05:35:57.006373+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_101040 | REC_0000691 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 14.2 | 65 | male | 1 | 25 | 2.5 | 1 | sotorasib 960 mg daily | 14.6 | true | MSI-H | 2026-03-15T05:35:57.006615+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_334642 | REC_0000692 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 12.5 | 64 | female | 1 | 21 | 5.7 | 1 | sotorasib 960 mg daily | 14.8 | true | MSI-H | 2026-03-15T05:35:57.006852+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_798667 | REC_0000693 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 5.6 | 68 | male | 1 | 57 | 5.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 10 | false | MSS | 2026-03-15T05:35:57.007087+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_360704 | REC_0000694 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 16.3 | 65 | male | 1 | 19 | 7.7 | 1 | osimertinib 80 mg daily | 17.4 | true | MSI-H | 2026-03-15T05:35:57.007321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_710750 | REC_0000695 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 3.9 | 69 | female | 1 | 58 | 6.9 | 7 | carboplatin + paclitaxel + pembrolizumab | 10.3 | false | MSS | 2026-03-15T05:35:57.007549+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_971515 | REC_0000696 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 15.2 | 71 | female | 1 | 12 | 7.5 | 5 | alectinib 600 mg BID | 9.3 | true | MSI-H | 2026-03-15T05:35:57.007787+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_413860 | REC_0000697 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 13.1 | 48 | female | 0 | 12 | 4.7 | 2 | sotorasib 960 mg daily | 15.8 | true | MSS | 2026-03-15T05:35:57.008023+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_703472 | REC_0000698 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 15.8 | 73 | male | 2 | 16 | 4 | 5 | pembrolizumab 200 mg q3w | 13.4 | true | MSS | 2026-03-15T05:35:57.008308+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_280602 | REC_0000699 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 21.7 | 51 | female | 0 | 19 | 4.3 | 6 | osimertinib 80 mg daily | 9.6 | true | MSI-H | 2026-03-15T05:35:57.008545+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_115514 | REC_0000700 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 15.9 | 68 | male | 1 | 18 | 6.2 | 5 | osimertinib 80 mg daily | 5.2 | true | MSS | 2026-03-15T05:35:57.008779+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.